# Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

> **NCT07643831** · — · AVAILABLE · sponsor: **Genentech, Inc.**

## Conditions studied

- ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer

## Interventions

- **DRUG:** Giredestrant

## Key facts

- **NCT ID:** NCT07643831
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643831, "Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*